Clinical Trial Update: AP301 Efficacy and Safety in Chinese Dialysis Patients With Hyperphosphatemia [Phase 3]

View source ↗

Summary

Phase 3 trial of AP301 for hyperphosphatemia in Chinese dialysis patients has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Kidney Disease
• End-stage Renal Disease
• Hyperphosphatemia

Drugs mentioned

• AP301

Snippet

Sponsor: Alebund Pharmaceuticals | Conditions: ESRD (End Stage Renal Disease), Chronic Kidney Disease(CKD) | Phase 3 | Status: COMPLETED